- Home
- AIM vs COSM Comparison
AIM vs COSM Comparison
Compare AIM & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- COSM
- Stock Information
- Founded
- AIM 1966
- COSM 2009
- Country
- AIM United States
- COSM United States
- Employees
- AIM N/A
- COSM N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- COSM Other Pharmaceuticals
- Sector
- AIM Health Care
- COSM Health Care
- Exchange
- AIM Nasdaq
- COSM Nasdaq
- Market Cap
- AIM 15.9M
- COSM 17.7M
- IPO Year
- AIM N/A
- COSM 2013
- Fundamental
- Price
- AIM $0.20
- COSM $0.66
- Analyst Decision
- AIM Strong Buy
- COSM
- Analyst Count
- AIM 2
- COSM 0
- Target Price
- AIM $2.75
- COSM N/A
- AVG Volume (30 Days)
- AIM 403.8K
- COSM 161.6K
- Earning Date
- AIM 11-15-2024
- COSM 11-14-2024
- Dividend Yield
- AIM N/A
- COSM N/A
- EPS Growth
- AIM N/A
- COSM N/A
- EPS
- AIM N/A
- COSM N/A
- Revenue
- AIM $190,000.00
- COSM $56,042,109.00
- Revenue This Year
- AIM N/A
- COSM $4.53
- Revenue Next Year
- AIM $1,086.80
- COSM $25.00
- P/E Ratio
- AIM N/A
- COSM N/A
- Revenue Growth
- AIM N/A
- COSM 13.01
- 52 Week Low
- AIM $0.16
- COSM $0.47
- 52 Week High
- AIM $0.62
- COSM $1.65
- Technical
- Relative Strength Index (RSI)
- AIM 40.44
- COSM 34.83
- Support Level
- AIM $0.20
- COSM $0.69
- Resistance Level
- AIM $0.23
- COSM $0.73
- Average True Range (ATR)
- AIM 0.02
- COSM 0.05
- MACD
- AIM 0.00
- COSM -0.01
- Stochastic Oscillator
- AIM 10.75
- COSM 0.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.